STAT says new retatrutide data leave heart benefit unresolved
Fresh results for Eli Lilly's triple hormone receptor agonist did not settle whether the drug delivers cardiovascular protection.
MH
By Maren Holt · Senior Reporter, GLP-1
Jul 23 03:00 ETSource: STAT
The wire
- 01STAT reports that newly released data on Eli Lilly's retatrutide, a GLP-1, GIP and glucagon receptor agonist, leave open questions about cardiovascular benefit.
- 02Cardiovascular outcomes have become a key differentiator among obesity drugs for payers and prescribers, so ambiguity affects how retatrutide would be positioned against semaglutide and tirzepatide.
- 03Definitive answers would require dedicated cardiovascular outcomes data; retatrutide remains investigational and unapproved.
From the source
Read at statnews.comNew data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
